Sutro Biopharma Inc (STRO) Stock Price, Quote & News

Company Profile

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 881 6500

Fax: 650 553 9659

Website: www.sutrobio.com

Address:

111 Oyster Point Boulevard, South San Francisco, United States

Send_IT_or_stepaside Jun. 4 at 5:40 PM

$AUPH what’s it like being in a stoke that goes up, holds and continues for months $STRO

1 · Reply

topstockalerts Jun. 4 at 2:26 AM

$STRO the path of least resistance appears to be higher.

0 · Reply

KY3000 Jun. 3 at 11:16 PM

$STRO c suite sticking by pdx models on 004 with data due.

0 · Reply

TheDragonsClaw Jun. 3 at 10:48 PM

$YDES $IVF $CHSN $STRO XP

0 · Reply

topstockalerts Jun. 3 at 9:31 PM

$STRO the chart has a very steady heartbeat today.

1 · Reply

KY3000 Jun. 3 at 9:02 PM

$STRO I noticed chow got RSU yesterday, weird to me is he paid cash for the tax instead of selling shares. I never seen that before

0 · Reply

DCZ Jun. 3 at 8:53 PM

$STRO someone get a sneak peak of the data? BO rumor? Big short covering?

1 · Reply

Zaksab Jun. 3 at 8:42 PM

$STRO data very soon?….

0 · Reply

KY3000 Jun. 2 at 9:49 PM

$STRO vax A1 dosed from vaxcyte, further validating STRO tech

0 · Reply

KY3000 Jun. 2 at 7:23 PM

$STRO bro they going deep

1 · Reply

Sutro Biopharma Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T09:31:18.000Z - 8 days ago

Sutro Biopharma initiated with an Overweight at Barclays

May 27, 2026, 12:30 PM EDT - 8 days ago

Sutro Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

2026-05-22T11:54:22.000Z - 13 days ago

Sutro Biopharma price target raised to $10 from $9 at BofA

2026-05-15T12:10:28.000Z - 20 days ago

Wedbush upgrades Sutro Biopharma to Outperform, raises price target to $60

2026-05-15T10:44:31.000Z - 20 days ago

Sutro Biopharma upgraded to Outperform from Neutral at Wedbush

2026-05-15T10:17:52.000Z - 20 days ago

Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright

2026-05-15T10:15:28.000Z - 20 days ago

Sutro Biopharma price target raised to $43 from $38 at Leerink

2026-05-14T20:40:52.000Z - 21 days ago

Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21)

May 14, 2026, 4:05 PM EDT - 21 days ago

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

May 14, 2026, 4:00 PM EDT - 21 days ago

Sutro Biopharma Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 21 days ago

Sutro Biopharma Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 21 days ago

Sutro Biopharma Slides: Corporate presentation

2026-04-30T09:15:15.000Z - 5 weeks ago

Sutro Biopharma initiated with an Outperform at Mizuho

2026-04-23T09:40:15.000Z - 6 weeks ago

Sutro Biopharma price target raised to $41 from $35 at Citizens

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

Sutro Biopharma Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

Sutro Biopharma Proxy statement: Proxy filing

2026-04-20T00:50:26.000Z - 6 weeks ago

Sutro Biopharma presents preclinical data across its pipeline of ADCs

2026-04-17T09:40:13.000Z - 7 weeks ago

Sutro Biopharma price target raised to $35 from $23 at Citizens

2026-04-13T19:37:51.000Z - 7 weeks ago

Sutro Biopharma management to meet with Citizens

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Sutro Biopharma Slides: Corporate presentation

2026-04-07T10:50:38.000Z - 2 months ago

Sutro Biopharma initiated with an Outperform at Leerink

2026-03-25T12:51:43.000Z - 2 months ago

Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank

2026-03-24T10:15:26.000Z - 2 months ago

Sutro Biopharma upgraded to Buy from Neutral at H.C. Wainwright

2026-03-24T09:55:11.000Z - 2 months ago

Wells upgrades Sutro to Overweight ahead of STRO-004 data

2026-03-24T01:35:11.000Z - 2 months ago

Sutro Biopharma upgraded to Overweight from Equal Weight at Wells Fargo

Mar 23, 2026, 5:00 PM EDT - 2 months ago

Sutro Biopharma Annual report: Q4 2025

Mar 23, 2026, 5:00 PM EDT - 2 months ago

Sutro Biopharma Earnings release: Q4 2025

Mar 23, 2026, 4:05 PM EDT - 2 months ago

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Mar 23, 2026, 8:00 AM EDT - 2 months ago

Sutro Biopharma Registration statement: Registration filing

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Sutro Biopharma Slides: Corporate presentation

Mar 10, 2026, 1:05 PM EDT - 3 months ago

Sutro Biopharma Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 1:50 PM EST - 3 months ago

Sutro Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:30 AM EST - 3 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Feb 10, 2026, 7:00 AM EST - 4 months ago

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Jan 15, 2026, 2:15 PM EST - 5 months ago

Sutro Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 2:15 PM EST - 5 months ago

Sutro Biopharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 10, 2026, 7:00 AM EST - 5 months ago

Sutro Biopharma Slides: Corporate presentation

Dec 3, 2025, 3:30 PM EST - 6 months ago

Sutro Biopharma Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 7 months ago

Sutro Biopharma Transcript: R&D Day 2025

Nov 12, 2025, 10:00 AM EST - 7 months ago

Sutro Biopharma Press release: FY 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:00 PM EST - 7 months ago

Sutro Biopharma Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Sutro Biopharma Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Sutro Biopharma Slides: Corporate Presentation

Nov 5, 2025, 4:05 PM EST - 7 months ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Sep 29, 2025, 5:05 PM EDT - 8 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sep 3, 2025, 2:15 PM EDT - 9 months ago

Sutro Biopharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 6:00 PM EDT - 9 months ago

Sutro Biopharma Slides: Corporate Presentation

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Sutro Biopharma Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Sutro Biopharma Earnings release: Q2 2025

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Sutro Biopharma Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 11:00 AM EDT - 1 year ago

Sutro Biopharma Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 13, 2025, 7:35 PM EDT - 1 year ago

Sutro Biopharma Transcript: Bank of America 2025 Healthcare Conference

May 8, 2025, 4:31 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:00 PM EDT - 1 year ago

Sutro Biopharma Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Sutro Biopharma Quarterly report: Q1 2025

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Sutro Biopharma Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Sutro Biopharma Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Sutro Biopharma Proxy statement: Proxy Filing

Mar 15, 2025, 6:40 PM EDT - 1 year ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Sutro Biopharma Earnings Call Transcript: Q4 2024

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Sutro Biopharma Annual report: Q4 2024

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Sutro Biopharma Earnings release: Q4 2024

Mar 4, 2025, 2:30 PM EST - 1 year ago

Sutro Biopharma Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Jan 15, 2025, 5:15 PM EST - 1 year ago

Sutro Biopharma Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

Sutro Biopharma Slides: FY 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 4:00 PM EST - 1 year ago

Sutro Biopharma Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 2:30 PM EST - 1 year ago

Sutro Biopharma Transcript: JMP Hematology and Oncology Summit 2024

Nov 21, 2024, 7:30 AM EST - 1 year ago

Sutro Biopharma Transcript: Jefferies London Healthcare Conference 2024

Nov 21, 2024, 7:30 AM EST - 1 year ago

Sutro Biopharma Slides: FY 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 13, 2024, 4:00 PM EST - 1 year ago

Sutro Biopharma Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Sutro Biopharma Earnings release: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Oct 10, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Transcript: Status Update

Oct 10, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Slides: Status Update

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sep 5, 2024, 3:00 PM EDT - 1 year ago

Sutro Biopharma Transcript: 2024 Wells Fargo Healthcare Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Sutro Biopharma Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Sutro Biopharma Earnings release: Q2 2024

Jun 3, 2024, 10:00 AM EDT - 2 years ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

May 17, 2024, 8:00 AM EDT - 2 years ago

Sutro Biopharma Proxy statement: Proxy Filing

May 13, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

May 13, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Quarterly report: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Earnings release: Q1 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Sutro Biopharma Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Sutro Biopharma Proxy statement: Proxy Filing

Apr 2, 2024, 6:18 AM EDT - 2 years ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 1:00 AM EDT - 2 years ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024, 5:30 PM EDT - 2 years ago

Sutro Biopharma Earnings release: Q4 2023

Mar 25, 2024, 5:30 PM EDT - 2 years ago

Sutro Biopharma Annual report: Q4 2023

Mar 25, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jan 4, 2024, 4:30 PM EST - 2 years ago

Sutro Biopharma Transcript: Study Update

Jan 4, 2024, 4:30 PM EST - 2 years ago

Sutro Biopharma Slides: Study Update

Jan 4, 2024, 4:05 PM EST - 2 years ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 14, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

$Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023$

Dec 11, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 21, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Quarterly report: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Sutro Biopharma Registration statement: Registration Filing

Oct 22, 2023, 4:25 AM EDT - 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 16, 2023, 4:05 PM EDT - 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Transcript: Citi 18th Annual BioPharma Conference

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Quarterly report: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Earnings release: Q2 2023

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 3, 2023, 4:00 PM EDT - 3 years ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

May 31, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 15, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 15, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Quarterly report: Q1 2023

May 15, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Earnings release: Q1 2023

May 8, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Proxy statement: Proxy Filing

Apr 27, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 18, 2023, 1:30 PM EDT - 3 years ago

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Sutro Biopharma Proxy statement: Proxy Filing

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Earnings release: Q4 2022

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Sutro Biopharma Annual report: Q4 2022

Mar 17, 2023, 4:01 PM EDT - 3 years ago

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Send_IT_or_stepaside Jun. 4 at 5:40 PM

$AUPH what’s it like being in a stoke that goes up, holds and continues for months $STRO

1 · Reply

topstockalerts Jun. 4 at 2:26 AM

$STRO the path of least resistance appears to be higher.

0 · Reply

KY3000 Jun. 3 at 11:16 PM

$STRO c suite sticking by pdx models on 004 with data due.

0 · Reply

TheDragonsClaw Jun. 3 at 10:48 PM

$YDES $IVF $CHSN $STRO XP

0 · Reply

topstockalerts Jun. 3 at 9:31 PM

$STRO the chart has a very steady heartbeat today.

1 · Reply

KY3000 Jun. 3 at 9:02 PM

$STRO I noticed chow got RSU yesterday, weird to me is he paid cash for the tax instead of selling shares. I never seen that before

0 · Reply

DCZ Jun. 3 at 8:53 PM

$STRO someone get a sneak peak of the data? BO rumor? Big short covering?

1 · Reply

Zaksab Jun. 3 at 8:42 PM

$STRO data very soon?….

0 · Reply

KY3000 Jun. 2 at 9:49 PM

$STRO vax A1 dosed from vaxcyte, further validating STRO tech

0 · Reply

KY3000 Jun. 2 at 7:23 PM

$STRO bro they going deep

1 · Reply

Zaksab Jun. 2 at 4:07 PM

$STRO it’s clear that there are no desperately eager buyers here until post data

0 · Reply

KY3000 Jun. 2 at 2:17 PM

$STRO LFG Jane, get this 004 data ready for EHA, let’s get some partners

0 · Reply

KY3000 Jun. 2 at 2:02 PM

$STRO 9k volume, musa

0 · Reply

Zaksab Jun. 1 at 2:54 PM

$STRO should have presented at ASCO if data was decent?

2 · Reply

KY3000 May. 29 at 4:00 PM

$STRO 004 data mirror pdx data, best ADC play. Astellas will have 2 iadc(dual-payload) in clinic this year. Sutro has option to share US rights. This is going gangbuster

1 · Reply

Quantumup May. 28 at 11:11 AM

Barclays🏁 $STRO and said: We initiate coverage of Sutro Bio (STRO) at Overweight with a $56 price target. $PFE GMAB $ALPMY MRSN MGNX IDYA ABBV Here's what else Barclays had to say in its initiation report: https://x.com/Quantumup1/status/2059954928584462482?s=20

0 · Reply

KY3000 May. 27 at 5:21 PM

$STRO c suite stressing the PDX models, they updated CRC with 38% ORR/ tivdek 18% ORR

1 · Reply

KY3000 May. 27 at 5:00 PM

$STRO TD call real bullish on 004, data soon

0 · Reply

Bbboston May. 26 at 11:18 AM

$STRO This has a long way to go!

1 · Reply

KY3000 May. 22 at 8:01 PM

$STRO might hit 10$ next week, spacex ipo/tech taking all liquidity

2 · Reply

KY3000 May. 22 at 7:55 PM

$STRO real shitty weekend

0 · Reply

KY3000 May. 22 at 7:28 PM

$STRO 100 tute owned. They hate retail with a passion

0 · Reply

Market Cap	404.81M
Revenue (ttm)	102.48M
Net Income (ttm)	-191.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-186.47%
Debt to Equity Ratio	0.00

Volume	250,100
Avg Vol	278,754
Day's Range	N/A - N/A
Shares Out	16.57M
Stochastic %K	65%
Beta	1.54
Analysts	Strong Sell
Price Target	$48.17